Pre-made Lintuzumab biosimilar ( Whole mAb Radiolabelled, anti-CD33 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-314
Anti-CD33 therapeutic antibody (Pre-made Lintuzumab biosimilar,Whole mAb Radiolabelled) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Lintuzumab (SGN-33) is a humanized monoclonal antibody used in the treatment of cancer. The drug had been developed by Seattle Genetics as a treatment for acute myeloid leukemia (AML), a condition which results in the deaths of 9,000 people a year in the United States. Lintuzumab targets the CD33 protein, which is expressed in AML and other myeloproliferative diseases, but does not appear in abundance on normal cells.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-CD33 therapeutic antibody (Pre-made Lintuzumab biosimilar,Whole mAb Radiolabelled)|
|Format||Whole mAb Radiolabelled|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||PDL BioPharma;Seattle Genetics|
|Conditions Discontinued||Acute myeloid leukaemia;Myelodysplastic syndromes|